posaconazolum - Keputusan Carian

Singapura - Inggeris - HSA (Health Sciences Authority)

sinotrx posaconazole delayed release tablet 100mg

kingtop international trading pte ltd - posaconazole - tablet, delayed release - posaconazole 100 mg

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

posaconazol sandoz 100 mg gastro-resist. tabl.

sandoz sa-nv - posaconazol 100 mg - gastro-resistant tablet - posaconazole

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

posaconazol sandoz 100 mg gastro-resist. tabl.

sandoz sa-nv - posaconazol 100 mg - gastro-resistant tablet - posaconazole

Israel - Inggeris - Ministry of Health

noxafil 300 mg concentrate for solution for infusion

merck sharp & dohme israel ltd - posaconazole - concentrate for solution for infusion - posaconazole 300 mg/vial - posaconazole - noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults :- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate f

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

dp-posaconazole

douglas pharmaceuticals limited - posaconazole 40 mg/ml - oral suspension - 40 mg/ml - active: posaconazole 40 mg/ml excipient: citric acid monohydrate glucose liquid glycerol sodium citrate dihydrate 29.58% w/w (ph adjustment) citric acid monohydrate 20.79% w/w (ph adjustment) macrogol glycerol ricinoleate simethicone emulsion usp sodium benzoate sodium citrate dihydrate strawberry flavour titanium dioxide water xanthan gum - dp-posaconazole oral suspension is indicated for use in the treatment of the following invasive fungal infections in patients 18 years of age or older: - invasive aspergillosis in patients with disease that is refractory to, or are intolerant of, amphotericin b, itraconazole or voriconazole.

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

posaconazole teva 100 mg gastro-resist. tabl.

teva b.v. - posaconazol 100 mg - gastro-resistant tablet - posaconazole

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

posaconazole teva 100 mg gastro-resist. tabl.

teva b.v. - posaconazol 100 mg - gastro-resistant tablet - posaconazole